biostudies-literatureUnknown42(4)Michaeli DTMedizinische Fakultät Mannheim der Universität Heidelberg<h4>Background and objectives</h4>In South Africa, the prevalence of human papillomavirus (HPV) and associated diseases, such as cervical cancer and genital warts, is among the highest in the world. This study evaluates the cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV vaccination for 9- to 14-year-old girls from the South African healthcare system perspective.<h4>Methods</h4>A Markov model portraying the natural HPV disease progression from high-risk infection to cervical intraepithelial neoplasia (CIN) I, CIN II/III, or cervical cancer and from low-risk infection to genital warts was built. Transition probability, utility, and efficacy data were sourced from peer-reviewed literature. Vaccination costs were calculated based on the World Health Organization (WHO) guideliClinical drug investigation333-343https://www.ebi.ac.uk/biostudies/studies/S-EPMC8989937biostudies-literatureCost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa.PMC8989937Zhang WMarcus SMMichaeli JCMichaeli TMichaeli DTStoycheva SfalseCost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa.<h4>Background and objectives</h4>In South Africa, the prevalence of human papillomavirus (HPV) and associated diseases, such as cervical cancer and genital warts, is among the highest in the world. This study evaluates the cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV vaccination for 9- to 14-year-old girls from the South African healthcare system perspective.<h4>Methods</h4>A Markov model portraying the natural HPV disease progression from high-risk infection to cervical intraepithelial neoplasia (CIN) I, CIN II/III, or cervical cancer and from low-risk infection to genital warts was built. Transition probability, utility, and efficacy data were sourced from peer-reviewed literature. Vaccination costs were calculated based on the World Health Organization (WHO) guideli2022-01-01T00:00:00Z2022 Apr2025-04-22T19:12:26.566Z2025-04-06T02:39:07.6ZS-EPMC89899373529472610.1007/s40261-022-01138-6